Παρασκευή 25 Μαΐου 2018

Targeted Alpha Therapy using Radium-223: From physics to biological effects

S03057372.gif

Publication date: Available online 25 May 2018
Source:Cancer Treatment Reviews
Author(s): I.A. Marques, A.R. Neves, A.M. Abrantes, A.S. Pires, E. Tavares-da-Silva, A. Figueiredo, M.F. Botelho
With the advance of the use of ionizing radiation in therapy, targeted alpha therapy (TAT) has assumed an important role around the world. This kind of therapy can potentially reduce side effects caused by radiation in normal tissues and increased destructive radiobiological effects in tumor cells. However, in many countries, the use of this therapy is still in a pioneering phase. Radium-223 (223Ra), an alpha-emitting radionuclide, has been the first of its kind to be approved for the treatment of bone metastasis in metastatic castration-resistant prostate cancer. Nevertheless, the interaction mechanism and the direct effects of this radiopharmaceutical in tumor cells are not fully understood neither characterized at a molecular level. In fact, the ways how TAT is linked to radiobiological effects in cancer is not yet revised. Therefore, this review introduces some physical properties of TAT that leads to biological effects and links this information to the hallmarks of cancer. The authors also collected the studies developed with 223Ra to correlate with the three categories reviewed - properties of TAT, 5 R's of radiobiology and hallmarks of cancer- and with the promising future to this radiopharmaceutical.



https://ift.tt/2J8HrZ3

Neratinib: Inching up on the cure rate of HER2+ breast cancer?

Neratinib was recently approved by FDA for extended adjuvant treatment of HER-2 positive breast cancer. ExteNET trial showed improvement in invasive disease-free survival (iDFS) in the neratinib arm compared to placebo. The benefit was more pronounced in patients with ER+/HER2+ tumors, suggesting bidirectional crosstalk between the two pathways.



https://ift.tt/2INwxss

The protein tyrosine phosphatase activity of Eyes Absent contributes to tumor angiogenesis and tumor growth

DNA damage repair capacity is required for cells to survive catastrophic DNA damage and proliferate under conditions of intra-tumoral stress. The ability of the minor histone protein H2AX to serve as a hub for the assembly of a productive DNA damage repair complex is a necessary step in preventing DNA damage-induced cell death. The Eyes Absent (EYA) proteins dephosphorylate the terminal tyrosine residue of H2AX thus permitting assembly of a productive DNA repair complex. Here we use genetic and chemical biology approaches to separately query the roles of host vascular endothelial cell and tumor cell EYA in tumor growth. Deletion of Eya3 in host endothelial cells significantly reduced tumor angiogenesis and limited tumor growth in xenografts. Deletion of Eya3 in tumor cells reduced tumor cell proliferation and tumor growth without affecting tumor angiogenesis. A chemical inhibitor of the EYA tyrosine phosphatase activity inhibited both tumor angiogenesis and tumor growth. Simultaneously targeting the tumor vasculature and tumor cells is an attractive therapeutic strategy since it could counter the development of the more aggressive phenotype known to emerge from conventional anti-angiogenic agents.



https://ift.tt/2KV0nYJ

Quantitative Phosphoproteomics Reveals Wee1 Kinase as a Therapeutic Target in a Model of Proneural Glioblastoma



https://ift.tt/204q3TO

Daily IGRT for prostate cancer: Can we stop the train?

We read with interest the phase III randomized trial by Tøndel and colleagues [1] comparing weekly portal imaging and daily CBCT. Specifically, two strategies of IGRT were compared, either daily control to correct for both systematic and random errors or weekly control to correct for systematic error only. Noteworthy, in the weekly IGRT arm, a larger PTV was adopted to reduce the risk of recurrence, but also a rectal block to reduce the risk of toxicity potentially related to the larger PTV of this group of patients.

https://ift.tt/2J1IKZZ

Evaluation of a magnetic resonance guided linear accelerator for stereotactic radiosurgery treatment

The purpose of this study was to investigate the systematic localization accuracy, treatment planning capability, and delivery accuracy of an integrated magnetic resonance imaging guided Linear Accelerator (MR-Linac) platform for stereotactic radiosurgery.

https://ift.tt/2GPBlYr

eIF2β, a subunit of translation‐initiation factor EIF2, is a potential therapeutic target for non‐small cell lung cancer

Cancer Science, EarlyView.


https://ift.tt/2KVGr7U